AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II

But Will Benefits Be Enough?

Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?

AriBio Co., Ltd. intends to file for approval to begin a Phase III US trial with its first-in-class oral therapy for Alzheimer’s disease AR1001, after Phase II results showed an improvement in cognitive functions from baseline along with safety and tolerability, the South Korean bioventure has said.

Preclinical studies with the molecule have confirmed it acts via multiple novel pharmacological mechanisms, including inhibition of neuronal apoptosis and...